Peptide Detection in Dried Blood Spots: What the 2026 Analytical Workflow Study Means for Patients

As peptide therapy continues to gain traction in longevity and regenerative medicine, one of the most common questions I receive from patients is straightforward: *How are these compounds actually measured and monitored?* A landmark 2026 study published in *The Analyst* by researchers at Ghent University's Doping Control Laboratory answers that question with remarkable clarity — and the findings carry meaningful implications for anyone currently using or considering peptide protocols.

Researchers Mazzarino, Colpaert, Deventer, and Van Eenoo developed and validated a rapid, streamlined analytical workflow capable of detecting **54 prohibited peptidic and non-peptidic compounds** across three blood matrix types: dried blood spots (DBS), serum, and plasma. Using liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS), the team engineered a single microextraction step — replacing the labor-intensive multi-step procedures that have historically made peptide testing expensive and slow.

The sample preparation protocol required only 500 µL of a methanol/water (8:2, v/v) mixture, dramatically simplifying what had previously been a cumbersome process. The study is notable not only for its methodological innovation but also for the breadth of compounds it covers, including peptides highly relevant to clinical and performance wellness contexts: BPC-157, TB500, ibutamoren (MK-677), AOD9604, kisspeptin-10, buserelin, vasopressin, and several LHRH analogues.

From a physician's perspective, this study is significant on multiple levels. First, it establishes that dried blood spot testing is a robust, practical alternative to conventional venous blood collection for peptide monitoring. DBS samples can be collected at home, shipped at room temperature, and processed without degradation — an enormous advantage for telehealth-based peptide therapy practices where in-person phlebotomy is not always feasible.

Second, the stability data for individual peptides is clinically instructive. The finding that **alexamorelin, AOD9604, buserelin, hGH 176-191, kisspeptin-10, and LHRH degrade rapidly in serum and plasma at room or refrigerator temperatures** has direct implications for specimen handling protocols. If a patient's sample is not processed promptly, clinicians may receive falsely low or negative results for these compounds — leading to misinterpretation of therapy adherence or dosing.

Third, the fact that **BPC-157 and TB500 degrade in serum but not in dried matrices** reinforces the practical superiority of DBS collection for monitoring these specific peptides in a real-world clinical setting.

If you are currently on a peptide protocol — whether that involves BPC-157 for gut and connective tissue repair, TB500 for injury recovery, or ibutamoren for growth hormone optimization — this research provides reassurance that accurate, accessible monitoring tools exist. You do not need to visit a specialty lab or undergo intravenous blood draws for reliable peptide quantification. Dried blood spot cards, which can be completed with a simple fingerstick at home, now represent a validated and scientifically sound method for tracking these compounds.

For patients concerned about privacy, convenience, or cost, DBS-based peptide monitoring is increasingly the gold standard. I use this framework when designing monitoring protocols for patients in my practice, and this study validates that approach at the highest scientific level.

This research was conducted within a **doping control context**, meaning the primary intent was detection and prohibition — not therapeutic dose-response monitoring. Detection limits, while impressive, were optimized for identifying prohibited use rather than titrating clinical dosages. Additionally, the study does not address **pharmacokinetic profiles** or **therapeutic windows** for the peptides examined. The 54-compound panel, while broad, does not cover every peptide in clinical use today. Finally, validation was performed in a single, highly specialized laboratory environment, and real-world reproducibility across diverse clinical labs has yet to be established.